Brain cholinesterases: III. Future perspectives of AD research and clinical practice

Medical Hypotheses

Volumn 63, Issue 2, 2004, Pages 298-307

  Shen, Z X ^a  

^a 55427 5011 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ALPHA TOCOPHEROL; BIOLOGICAL MARKER; BRAIN ENZYME; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CITICOLINE; GALACTOSE; LEVACECARNINE; LITHIUM; MECLOFENOXATE; NALOXONE; NOOTROPIC AGENT; PHENYLALANINE; SELEGILINE;

ALZHEIMER DISEASE; BRAIN DEPTH STIMULATION; BRAIN METABOLISM; CHOLINERGIC ACTIVITY; CLINICAL PRACTICE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ANALYSIS; ENZYME DEFICIENCY; ENZYME INHIBITION; ENZYME METABOLISM; EXPERIMENTAL ANIMAL; GENETIC ASSOCIATION; GENETIC CORRELATION; HOMEOSTASIS; HUMAN; MEDICAL RESEARCH; MOLECULAR DYNAMICS; NEUROCHEMISTRY; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STIMULATION;

EID: 3242769206     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.03.001     Document Type: Article

References (91)

1. Shen Z.X. The significance of the activity of CSF cholinesterases in dementias. Med. Hypotheses. 47:1996;363-376
2. Arendt T., Bruckner M.K., Lange M., Bigl V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development - a study of molecular forms. Neurochem. Int. 21:1992;381-396
3. Bohnen N.I., Kaufer D.I., Ivanco L.S., et al. Cortical cholinergic function is more severely affected in Parkinsonian dementia than in Alzheimer disease an in vivo positron emission tomographic study. Arch. Neurol. 60:2003;1745-1748
4. Elias M.F., Beiser A., Wolf P.A., et al. The preclinical phase of Alzheimer disease: a 22-year prospective study of the framingham cohort. Arch. Neurol. 57(6):2000;808-813
5. Small B.J., Mobly J.L., Laukka E.J., et al. Cognitive deficits in preclinical Alzheimer's disease. Acta Neurol. Scand. Suppl. 179:2003;29-33
6. Soreq H., Seidman S. Acetylcholinesterase - new roles for an old actor. Nat. Rev. Neurosci. 2(4):2001;294-302
7. Stoilov P., Meshorer E., Gencheva M., et al. Defects in pre-mRNA processing as causes of and predisposition to diseases. DNA Cell Biol. 21(11):2002;803-818
8. Taylor P, Luo ZD, Camp S. The genes encoding the cholinesterases: structure, evolutionary relationships and regulation of their expression. In: Gacobini E, editor. Cholinesterases and cholinesterase inhibitors. 1st ed. London: Martin Dunitz, 2000, p. 63-79
9. Massouli J. Molecular forms and anchoring of acetylcholinesterae. 1st ed. Giacobini E. Cholinesterases and cholinesterase inhibitors. 6:2000;81-101 Martin Dunitz, London
10. Silman I, Sussman J.L. Structural studies on acetylcholinesterase. 1st ed. Giacobini E. Cholinesterases and cholinesterase inhibitors. 2:2000;9-25 Martin Dunitz, London
11. Quinn D.M. Acetylcholinesterase: enzyme structure, reaction dynamics, and virtual transition states. Chem. Rev. 87:1987;955-979
12. Mesulam M.M., Guillozet A., Shaw P., Quinn B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol. Dis. 9:2002;88-93
13. Darvesh S., Hopkins D.A., Geula C. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci. 4:2003;131-138
14. Saez-Valero J., Small D.H. Acetylcholinesterase and butyrylcholinesterase glycoforms are biomarkers of Alzheimer's disease. J. Alzheimer's Dis. 3:2001;323-328
15. Li B., Stribley J.A., Ticu A., et al. Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. J. Neurochem. 75(3):2000;1320-1331
16. Balasubramanian A.S. Amyloid beta peptide processing, insulin degrading enzyme, and butyrylcholinesterase. Neurochem. Res. 26(4):2001;453-456
17. Mesulam M.M. Neuroanatomy of cholinesterases in the normal human brain and in Alzheimer's disease. Giacobini E. Cholinesterases and cholinesterase inhibitors. 1st ed.:2000;121-138 Martin Dunitz, London
18. Mesulam M.M., Geula C. Acetylcholinesterase-rich neurons of the human cerebral cortex: cytoarchitectonic and ontogenetic patterns of distribution. J. Comp. Neurol. 306:1991;193-220
19. 11C] physostigmine and positron emission tomography. J. Cereb. Blood Flow Metab. 21:2001;114-131
20. Meier-Ruge W., Ulrich J., Bruhlmann M., Meier E. Age-related white matter atrophy in the human brain. Ann. NY Acad. Sci. 673:1992;260-269
21. Amaducci L., Sorbi S., Piacentini S., Bick K. The first Alzheimer disease case: a metachromatic leukodystrophy. Dev. Neurosci. 13:1991;186-187
22. Brown W.R., Moody D.M., Thore C.R., Challa V.R. Cerebrovascular pathology in Alzheimer's disease and leukoaraiosis. Ann. NY Acad. Sci. 903:2000;39-45
23. Sturchler-Pierrat C., Abramowski D., Duke M., et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA. 94:1997;13287-13292
24. Gotz J., Chen F., Barmettler R., Nitsch R.M. Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem. 276:2001;529-534
25. Appleyard M.A. Secreted acetylcholinesterase: non-classical aspects of a classical enzyme. Trends Neurosci. 15(12):1992;485-490
26. Shen Z.X. CSF cholinesterase activity in demented and non-demented subjects. NeuroReport. 9:1998;483-488
27. Massiah M.A., Viragh C., Reddy P.M., et al. Short, strong hydrogen bonds as the active site of human acetylcholinesterase: proton NMR studies. Biochemistry. 40(19):2001;5682-5690
28. Saez-Valero J., Sberna G., McLean C.A., Small D.H. Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease. J. Neurochem. 72:1999;1600-1608
29. Inestrosa N.C., Alvarez A., Perez C.A., et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron. 16(4):1996;881-891
30. Guillozet A.L., Smiley J.F., Mash D.C., et al. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann. Neurol. 42(6):1997;909-918
31. Couderc R. Search of biological markers of Alzheimer's disease. Ann. Biol. Clin. (Paris). 58(5):2000;581-593
32. Yamamoto Y., Nakano S., Kawashima S., et al. Plasma and serum G4 isoenzyme of acetylcholinesterase in patients with Alzheimer-type dementia and vascular dementia. Ann. Clin. Biochem. 27(pt 4):1990;321-326
33. Inestrosa N.C., Alarcon R., Arriagada J., Donoso A., Alvarez J., Campos E.O. Blood markers in Alzheimer disease: subnormal acetylcholinesterase and butyrylcholinesterase in lymphocytes and erythrocytes. J. Neurol. Sci. 122:1994;1-5
34. Giacobini E. Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy. Giacobini E. Cholinesterases and cholinesterase inhibitors. 1st ed.:2000;181-226 Martin Dunitz, London
35. Wright C.I., Geula C., Mesulam M.M. Protease inhibitors and indoleamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90:1993;683-686
36. Mimori Y., Nakamura S., Yukawa M. Abnormalities of acetylcholinesterase in Alzheimer's disease with special reference to effect of acetylcholinesterase inhibitor. Behavio. Brain Res. 83:1997;25-30
37. Kasa P., Papp H., Kasa P. Jr., Torok I. Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzyme-positive structures in the human and rat brain. Neuroscience. 101(1):2000;89-100
38. Kuhl D.E., Minoshima S., Frey K.A., et al. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann. Neurol. 48:2000;391-395
39. Shinotoh H., Aotsuka A., Fukushi K., et al. Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology. 56(3):2001;408-410
40. Lockridge O., Masson P. Pesticides and susceptible populations: people with butyrylcholinesterase genetic variants may be at risk. Neuro. Toxicol. 21(1-2):2000;113-126
41. Gupta R.C., Milatovic D., Dettbarn W.D. Depletion of energy metabolites following acetylcholinesterase inhibitor-induced status epilepticus: protection by antioxidants. Neurotoxicology. 22(2):2001;271-282
42. Millard C.B., Broomfield C.A. Anticholinesterases: medical applications of neurochemical principles. J. Neurochem. 64:1995;1909-1918
43. Moretto A. Experimental and clinical toxicology of anticholinesterase agents. Toxicol. Lett. 102-3:1998;509-513
44. Karczmar A.G. Synaptic, behavioral, and toxicological effects of cholinesterase inhibitors in animals and humans. Giacobini E. Cholinesterases and cholinesterase inhibitors. 1st ed.:2000;157-180 Martin Dunitz, London
45. Baldi I., Lebailly P., Mohammed-Brahim B., et al. Neurodegenerative diseases and exposure to pesticides in the elderly. Am. J. Epidemiol. 157(5):2003;409-414
46. Hardy J.A., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:2002;353-356
47. Naslund J., Haroutunian V., Mohs R., et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 283(12):2000;1571-1577
48. Fodero L.R., Saez-Valero J., McLean C.A., et al. Altered glycosylation of acetylcholinesterase in APP SW Tg 2576 transgenic mice occurs prior to amyloid plaque deposition. J. Neurochem. 81(3):2002;441-448
49. Birks J.S., Melzer D., Beppu H. Donepezil for mild and moderate Alzheimer's disease. Cochrane. Database Syst. Rev. 4:2000;CD001190
50. Holmstedt B. Cholinesterase inhibitors: an introduction. Giacobini E. Cholinesterases and cholinesterase inhibitors. 1st ed.:2000;1-8 Martin Dunitz, London
51. Reiner E., Radic Z. Mechanism of action of cholinesterase inhibitors. Giacobini E. Cholinesterases and cholinesterase inhibitors. 1st ed.:2000;103-119
52. Pfeifer M., Boncristiano S., Bondolfi L., et al. Cerebral hemorrhage after passive anti-amyloid-beta immunotherapy. Science. 298:2002;1379-1380
53. Wolf H., Jelic V., Gertz H.J., et al. A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol. Scand. Suppl. 179:2003;52-76
54. Mayeux R., Tang M.X., Jacobs D.M., et al. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann. Neurol. 46:1999;412-416
55. Pratico D., Clark C.M., Liun F., et al. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch. Neurol. 59(6):2002;972-976
56. Devanand D.P., Michaels-marston K.S., Liu X., et al. Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. Am. J. Psychiat. 157:2000;1399-1405
57. Scinto L.F.M., Frosch M., Wu C.K., et al. Selective cell loss in Edinger-Westphal in asymptomatic elders and Alzheimer's patients. Neurobiol. Aging. 22:2001;729-736
58. Pettergrew J.W., Panchalingam K., Hamilton R.L., McClure R.J. Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res. 26(7):2001;771-782
59. Peretz B., Srivatsan M. Chronic stimulation increases acetylcholinesterase activity in old Aplysia. Behav. Brain Res. 80(1-2):1996;203-210
60. Wilson R.S., Mendes De Leon C.F., Barnes L.L. Mental stimulation linked to reduced Alzheimer's risk in older adults. JAMA. 287(6):2002;742-748
61. Scarmeas N., Levy G., Tang M.X., et al. Influence of leisure activity on the incidence of Alzheimer's disease. Neurology. 57:2001;2236-2242
62. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Wilson R.S. Vitamin E and cognitive decline in older persons. Arch. Neurol. 59:2002;1125-1132
63. Perkins A.J., Hendrie H.C., Callahan C.M., et al. Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey. Am. J. Epidemiol. 150(1):1999;37-44
64. Engelhart M.J., Geerlings M.I., Ruitenberg A., et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA. 287(24):2002;3223-3229
65. Tolbert S.R., Fuller M.A. Selegiline in treatment of behavioral and cognitive symptoms of Alzheimer disease. Ann. Pharmacother. 30:1996;1122-1129
66. Sano M., Ernesto C., Thomas R.G., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease cooperative study. N. Engl. J. Med. 336:1997;1216-1222
67. Shankaranarayana Rao B.S., Lakshmana M.K., Meti B.L., Raju T.R. Chronic (-) deprenyl administration alters dendritic morphology of layer III pyramidal neuons in the prefrontal cortex of adult Bonnett monkeys. Brain Res. 821:1999;218-223
68. Lakshmana M.K., Rao B.S., Dhingra N.K., et al. Chronic (-) deprenyl administration increases dendritic arborization in CA3 neurons of hippocampus and AChE activity in specific regions of the primate brain. Brain Res. 796:1998;38-44
69. Pettegrew J.W., Klunk W.E., Panchalingam K., Kanfer J.N., McClure R.J. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiol. Aging. 16:1995;1-4
70. Rani P.J., Panneerselvam C. Protective efficacy of L-carnitine on acetylcholinesterase activity in aged rat brain. J. Gerontol. A: Biol. Sci. Med. Sci. 56:2001;B140-B141
71. Gorini A., Ghigini B., Villa R.F. Acetylcholinesterase activity of synaptic plasma membranes during ageing: effect of L-acetylcarnitine. Dementia. 7(3):1996;147-154
72. Gimenez R., Soler S., Aguilar J. Cytidine diphosphate choline administration activates brain cytidine triphosphate: phosphocholine cytidylytransferase in aged rats. Neurosci. Lett. 273(3):1999;163-166
73. Attard G.S., Templer R.H., Smith W.S., Hunt A.N., Jackwski S. Modulation of CTP: phosphocholine cytidylyltransferase by membrane curvature elastic stress. Proc. Natl. Acad. Sci. USA. 97:2000;9032-9036
74. +-ATPase in adult rats. Clin. Biochem. 33:2000;351-357
75. Pek G., Fulop T., Zs-Nagy I. Gerontopsychological studies using NAI ('Nurnberger Alters-Inventar') on patients with psychosyndrome (DSM III, category 1) treated with centrophenoxine in a double blind, comparative, randomized clinical trial. Arch. Gerontol. Geriatr. 9:1989;17-30
76. Vaglenova J., Vesselinov Petkov V. Can nootropic drugs be effective against the impact of ethanol teratogenicity on cognitive performance. Eur. Neuropsychopharmacol. 11:2001;33-40
77. Sharma D., Singh R. Centrophenoxine activates acetylcholinesterase activity in hippocampus of aged rats. Indian J. Exp. Biol. 33:1995;365-368
78. Goldemberg A.L., Farias R.N., Trucco R.E. Erythrocyte membrane-bound acetylcholinesterase in vitamin E deficient rabbits. Comp. Biochem. Physiol. C. 99:1991;341-343
79. Southam E., Thomas P.K., King R.H., Goss-Sampson M.A., Muller D.P. Experimental vitamin E deficiency in rats. Morphological and functional evidence of abnormal axonal transport secondary to free radical damage. Brain. 114(Pt 2):1991;915-936
80. Lee L., Kang S.A., Lee H.O., et al. Effect of supplementation of vitamin E and vitamin C on brain acetylcholinesterase activity and neurotransmitter levels in rats treated with scopolamine, an inducer of dementia. J. Nutri. Sci. Vitaminol. 47(5):2001;323-328
81. Munoz F.J., Opazo C., Gil-Gomez G., et al. Vitamin E but not 17 beta-estradiol protects against vascular toxicity induced by beta-amyloid wild type and Dutch amyloid variant. J. Neurosci. 22(8):2002;3081-3089
82. Traber M.G., Packer L. Vitamin E: beyond antioxidant function. Am. J. Clin. Nutr. 62(Suppl 6):1995;1501S-1509S
83. +, K (+)-ATPase. Z. Naturforsch. C. 53:1998;163-167
84. Tsakiris S., Angelogianni P., Schulpis K.H., Stavridis J.C. Protective effect of L-phenylalanine on rat brain acetylcholinesterase inhibition induced by free radicals. Clin. Biochem. 33:2000;103-106
85. Gorini A., Rancati A., D'Angelo A., Devecchi E., Villa R.F. Effect of in vivo administration of naloxone on ATP-ase's enzyme systems of synaptic plasma membranes from rat cerebral cortex. Neurochem. Res. 25:2000;867-873
86. Tsakiris S., Schulpis K.H. The effect of galactose metabolic disorders on rat brain acetylcholinesterase activity. Z. Naturforsch. 55c:2000;852-855
87. Hong M., Chen D.C., Klein P.S., Lee V.M. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J. Biol. Chem. 272:1997;25326-25332
88. Alvarez G., Munoz-Montano J.R., Satrustegui J., et al. Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett. 453:1999;260-264
89. Kouniniotou-Krontiri P., Tsakiris S. Time-dependent effects of lithium on solubilised acetylcholinesterase of rat diaphragm. Med. Sci. Res. 24:1996;351-353
90. Rosenberg Y., Luo C., Ashani Y., et al. Pharmacokinetics and immunologic consequences of exposing macaques to purified homologous butyrylcholinesterase. Life Sci. 72(2):2002;125-134
91. Martin J.B. Molecular basis of the neurodegenerative disorders. N. Engl. J. Med. 340:1999;1970-1980